Guardant Health
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Guardant Health 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GH
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection.
CEOHelmy Eltoukhy
CEOHelmy Eltoukhy
Employees2,021
Employees2,021
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded2011
Founded2011
Employees2,021
Employees2,021
GH Key Statistics
Market cap7.98B
Market cap7.98B
Price-Earnings ratio-18.96
Price-Earnings ratio-18.96
Dividend yield—
Dividend yield—
Average volume2.53M
Average volume2.53M
High today$64.04
High today$64.04
Low today$61.70
Low today$61.70
Open price$63.20
Open price$63.20
Volume1.43M
Volume1.43M
52 Week high$68.00
52 Week high$68.00
52 Week low$20.14
52 Week low$20.14
GH News
Simply Wall St 2d
A Look at Guardant Health’s Valuation Following Expanded FDA Approval for Guardant360 CDx in Breast CancerGuardant Health (GH) just received expanded FDA approval for its Guardant360 CDx blood test. The test is now cleared to identify advanced breast cancer patients...
Simply Wall St 5d
How Investors Are Reacting To Guardant Health FDA Approval for New Breast Cancer Companion TestGuardant Health announced that the U.S. FDA has approved its Guardant360 CDx as a companion diagnostic to identify patients with specific ESR1 mutations who may...
Analyst ratings
88%
of 26 ratingsBuy
88.5%
Hold
7.7%
Sell
3.8%
People also own
Based on the portfolios of people who own GH. This list is generated using Robinhood data, and it’s not a recommendation.